東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Ligand-mediated approaches for the e...

Saul, Justin Michael.

FindBook

Google Book

Amazon

博客來

Ligand-mediated approaches for the enhancement of nanocarrier targeting to tumor cells.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Ligand-mediated approaches for the enhancement of nanocarrier targeting to tumor cells./
作者:	Saul, Justin Michael.
面頁冊數:	310 p.
附註:	Adviser: Ravi V. Bellamkonda.
Contained By:	Dissertation Abstracts International67-05B.
標題:	Engineering, Biomedical. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3218689
ISBN:	9780542703249

Ligand-mediated approaches for the enhancement of nanocarrier targeting to tumor cells.
Saul, Justin Michael.

Ligand-mediated approaches for the enhancement of nanocarrier targeting to tumor cells. - 310 p.

Adviser: Ravi V. Bellamkonda.

Thesis (Ph.D.)--Case Western Reserve University, 2006.

Novel approaches to treat tumors are requisite for improvements in the length and quality of life in cancer patients. Utilization of long-circulating nanocarriers, such as liposomes, bearing ligands directed at over-expressed surface receptors is one technique to direct large payloads of therapeutic agent to tumor cells with enhanced selectivity. Despite enhanced uptake of therapeutic agents in tumor cells with ligand-targeted nanocarriers, the ability to control the extent of cellular effects such as uptake of the nanocarrier or therapeutic effect has not been demonstrated.

ISBN: 9780542703249Subjects--Topical Terms:

1017684
Engineering, Biomedical.

Ligand-mediated approaches for the enhancement of nanocarrier targeting to tumor cells.
LDR:03476nam 2200337 a 45 001 964042
005 20110901
008 110901s2006 eng d
020 $a 9780542703249
035 $a (UMI)AAI3218689
035 $a AAI3218689
040 $a UMI $c UMI
100 1 $a Saul, Justin Michael. $3 1287115
245 1 0 $a Ligand-mediated approaches for the enhancement of nanocarrier targeting to tumor cells.
300 $a 310 p.
500 $a Adviser: Ravi V. Bellamkonda.
500 $a Source: Dissertation Abstracts International, Volume: 67-05, Section: B, page: 2697.
502 $a Thesis (Ph.D.)--Case Western Reserve University, 2006.
520 $a Novel approaches to treat tumors are requisite for improvements in the length and quality of life in cancer patients. Utilization of long-circulating nanocarriers, such as liposomes, bearing ligands directed at over-expressed surface receptors is one technique to direct large payloads of therapeutic agent to tumor cells with enhanced selectivity. Despite enhanced uptake of therapeutic agents in tumor cells with ligand-targeted nanocarriers, the ability to control the extent of cellular effects such as uptake of the nanocarrier or therapeutic effect has not been demonstrated.
520 $a The hypothesis motivating these studies was that the amount of a therapeutic agent (doxorubicin) delivered to cells and the response to the agent (cytotoxicity) could be controlled by modulation of the numbers and types of targeting ligands on the nanocarrier. Doxorubicin uptake and cytotoxicity were characterized and quantified for two different ligands---folic acid and a monoclonal antibody against the epidermal growth factor receptor (EGFR).
520 $a Targeting of liposomal nanocarriers with folic acid or the anti-EGFR antibody led to significantly increased doxorubicin uptake and cytotoxicity, relative to non-targeted nanocarriers, in cells bearing the targeted receptor. The amount of doxorubicin uptake was found to depend on the number of targeting ligands utilized.
520 $a After characterization of the two targeting ligands, nanocarriers simultaneously bearing both ligands were designed. Nanocarriers bore numbers of each ligand that alone were insufficient to elicit toxicity but when utilized together achieved a cytotoxic effect only in cells bearing both targeted receptors. The results of these dual ligand studies show that nanocarriers can be designed to bear appropriate numbers of targeting ligands for selectivity enhancement, thereby sparing cells not bearing both targeted receptors.
520 $a The results of these studies demonstrate the importance of controlling the numbers and types of targeting ligands. The results also suggest the necessity of optimizing combinations of ligands to enhance tumor selectivity. Increased understanding of the interplay between the number of targeting ligands and the available tumor cell surface receptors may ultimately allow for patient-specific targeting schemes based on the patient's tumor profile. In conjunction with other treatment modalities, properly designed targeted nanocarriers have the potential to aid in improved outcomes for cancer patients.
590 $a School code: 0042.
650 4 $a Engineering, Biomedical. $3 1017684
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0541
690 $a 0572
690 $a 0992
710 2 0 $a Case Western Reserve University. $3 1017714
773 0 $t Dissertation Abstracts International $g 67-05B.
790 $a 0042
790 1 0 $a Bellamkonda, Ravi V., $e advisor
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3218689